Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. - Seite 2

Dr. Roizen, Chief Wellness Officer Emeritus at Cleveland Clinic, emphasized Telomir-1's innovative approach to combating aging-related conditions, including diseases such as osteoarthritis, and highlighted the scientific principles underlying stem cell regulation.

Acknowledging the invaluable contributions of Telomir-1's expert panel (the GeorgeTown Group) on longevity which was formed in December 2023, Dr. Roizen expressed gratitude for their collaboration and dedication. The distinguished panel, comprising 14 individuals from the fields of medicine, medical ethics, public relations, law and economics, further demonstrates a multi-pronged approach in shaping Telomir-1's research direction.

“Sharing our pre-clinical results with the public was a significant step for Telomir, particularly with the strong interest in this important work that the longevity community has expressed,” said Dr. Roizen. “We are grateful for the support of our expert panel without whom this event would not have been possible. It gave us the opportunity to present our findings to the attendees and to share with them the progress Telomir is making toward developing and commercializing Telomir-1 to reverse age-related conditions.”

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and ultimately post-chemotherapy recovery and a broader range of other age-related inflammatory conditions such as osteoarthritis.

The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Telomir’s technologies potential in treating or reversing age-related conditions and Telomir-1’s ability to result in an individual’s ability to repair oneself by using Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company’s control) that could cause actual results (including the anticipated benefits of the pre-clinical data presented at the National Press Club as well as the actual timing for pre-clinical and clinical studies of Telomir-1 as discussed herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company’s website at https://ir.telomirpharma.com. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.